does microdosing glp 1 really work Why Are Fit Guys GLP-1s? How microdosing GLP-1 drugs became

However, its future trajectory is far from linear as many uncertainties remain, e.g., acceptance of obesity as a chronic disease, budget impact faced by payers and health systems willingness and ability to pay, the readout of further cardiovascular outcomes trials after the high profile results of 2023s SELECT trial for Wegovy, or new entrants challenging first generation therapies with alternative mechanisms of action (MoA) to address shortcomings such as gastrointestinal tolerability, current drugs being injectables, or the durability and quality of weight loss which distinguishes between fat and lean body mass

A UCLA study published in ACR Open Rheumatology found that GLP-1 receptor agonists such as semaglutide and tirzepatide may reduce rheumatoid arthritis activity and cardiovascular risk factors in people with obesity, suggesting potential dual benefits for metabolic and inflammatory health.

Members of $MED's Scientific and Clinical Affairs team and Medifasts Scientific Advisory Board recently published an article in Diabetes, Obesity and Metabolism, highlighting GLP-1 discontinuation rates

A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial results reported at AAIC.

In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D)

Rybelsus is the world's first oral GLP-1 receptor agonist